United Therapeutic (UTHR) Stock Price, Quote & News

Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to d...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 301 608 9292

Website: www.unither.com

Address:

1000 Spring Street, Silver Spring, United States

clan Jul. 15 at 9:38 AM

$UTHR $MNKD Do NOT ever forget what those pieces of SH¡T at $LQDA did to stop patients from receiving the more effective and efficient life-saving PH drug in Tyvaso DPI! Those shameless, corrupt, satan-worshipping, lying, thieving execs over at Liquidatia; along with their bunch of navel-gazing impish retail investors. @SteelerJon SHAME! Never forget!

1 · Reply

clan Jul. 14 at 7:45 PM

$MNKD @ItzaFugazi Question: If Teton 2 for IPF could jump $UTHR from current $297 to well over $500/sh, what would that mean for MNKD? Answer: A lot!

2 · Reply

JarvisFlow Jul. 10 at 4:09 PM

Morgan Stanley has adjusted their stance on United Therapeutics ( $UTHR ), setting the rating to Equal-Weight with a target price of 348 → 328.

0 · Reply

clan Jul. 10 at 2:37 PM

$MNKD Keep your ears open for TETON 2 update; IPF indication - huge market/potential. Mannkind-Danbury currently has the manufacturing capacity to service 25,000 Tyvaso DPI patients. For every 10,000 patients, Mannkind earns $250,000,000- $300,000,000 annually. $UTHR

2 · Reply

grampslol Jul. 9 at 2:47 PM

$UTHR Uh, oh... not good for tyfizzle or the afizzle company $MNKD https://www.businesswire.com/news/home/20250623646523/en/Merck-Announces-Phase-3-HYPERION-Study-of-WINREVAIR-sotatercept-csrk-Met-Primary-Endpoint-in-Recently-Diagnosed-Adults-with-Pulmonary-Arterial-Hypertension-PAH#xd_co_f=ODFjY2FmMjQtODdmOC00ZjZkLWJkODYtNmUwYmQ5MjgxMTEw~

0 · Reply

JarvisFlow Jul. 8 at 3:41 PM

JP Morgan updates rating for United Therapeutics ( $UTHR ) to Overweight, target set at 350 → 330.

0 · Reply

grampslol Jul. 8 at 3:10 PM

$MNKD $UTHR thanks ever so much for the re-hash tyfizzle dpi stuff @harryxl when $LQDA Yutrepia Dpi prevails in their 10898494 patent infringement case against uthr how soon will tyfizzle be pulled from the market ? Tia

0 · Reply

Harryx1 Jul. 8 at 2:56 PM

$MNKD $UTHR

2 · Reply

Harryx1 Jul. 8 at 2:42 PM

$MNKD $UTHR https://www.researchgate.net/publication/393364987_Practical_Considerations_for_Managing_Patients_on_Tyvaso_DPI_Treprostinil_Inhalation_Powder

1 · Reply

HanksterGangster Jul. 7 at 2:59 PM

$UTHR - indicators suggest good entry point towards filling the huge gap to $235. Slow recovery in the making.

0 · Reply

United Therapeutics and Intermountain Health Announce the First Patient Treated With External Liver Support Using a Bioengineered Liver

Jun 23, 2025, 7:00 AM EDT - 22 days ago

United Therapeutics Corporation Concludes Enrollment of the ADVANCE OUTCOMES Study of Ralinepag for the Treatment of Pulmonary Arterial Hypertension

Jun 11, 2025, 1:36 PM EDT - 4 weeks ago

United Therapeutics: Tanking On Rival's PAH Data - I'd Consider Buying Stock

Apr 30, 2025, 1:09 PM EDT - 2 months ago

United Therapeutics Corporation (UTHR) Q1 2025 Earnings Call Transcript

Apr 30, 2025, 6:30 AM EDT - 2 months ago

United Therapeutics Corporation Reports First Quarter 2025 Financial Results

Apr 21, 2025, 7:00 AM EDT - 3 months ago

United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2025 International Conference

Apr 4, 2025, 7:00 AM EDT - 3 months ago

United Therapeutics Corporation to Feature Clinical Data Across its Commercial and Development Portfolio at the International Society for Heart and Lung Transplantation 45th Annual Meeting and Scientific Sessions

Mar 29, 2025, 8:17 AM EDT - 3 months ago

United Therapeutics: Don't Fear The Patent Expiration Too Much

Mar 4, 2025, 7:00 AM EST - 4 months ago

United Therapeutics Corporation to Present at the Leerink Partners Global Healthcare Conference 2025

Feb 26, 2025, 2:14 PM EST - 4 months ago

United Therapeutics Corporation (UTHR) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 6:30 AM EST - 4 months ago

United Therapeutics Corporation Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 25, 2025, 1:06 AM EST - 5 months ago

United Therapeutics: A Unique Business With High Margins And Expansion Potential

Feb 24, 2025, 7:00 AM EST - 5 months ago

United Therapeutics Corporation to Present at the TD Cowen 45th Annual Health Care Conference

Feb 19, 2025, 7:00 AM EST - 5 months ago

United Therapeutics Corporation to Report Fourth Quarter and Full Year 2024 Financial Results Before the Market Opens on Wednesday, February 26, 2025

Feb 4, 2025, 7:00 AM EST - 5 months ago

United Therapeutics Corporation Announces Full Enrollment of the TETON 1 Study of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis

Feb 3, 2025, 7:00 AM EST - 5 months ago

United Therapeutics Corporation Announces FDA Clearance of its Investigational New Drug Application for the UKidney Xenotransplantation Clinical Trial

Jan 21, 2025, 7:00 AM EST - 6 months ago

United Therapeutics Corporation to Feature Clinical Data Across its Commercial and Development Portfolio at the Pulmonary Vascular Research Institute 2025 Annual Congress

Jan 6, 2025, 7:00 AM EST - 6 months ago

United Therapeutics Corporation to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 29, 2024, 4:25 PM EST - 7 months ago

The Zen Ten - My Top Picks For 2025

AAPL BBW IBKR INTU META NVDA TSM

Dec 17, 2024, 7:00 AM EST - 7 months ago

United Therapeutics Announces Successful World's First UKidney Transplant

Nov 15, 2024, 6:27 PM EST - 8 months ago

United Therapeutics: Competitive Advantages At Such Cheap Multiples Scream Buy

Nov 15, 2024, 7:00 AM EST - 8 months ago

United Therapeutics Expands Into Organ Transplants, But Tyvaso's Legal Battles Loom

Nov 14, 2024, 5:16 PM EST - 8 months ago

United Therapeutics: One To Believe In Despite Competitive Threats

Nov 5, 2024, 4:30 PM EST - 9 months ago

United Therapeutics Corporation to Present at the UBS Global Healthcare Conference

Oct 30, 2024, 3:09 PM EDT - 9 months ago

United Therapeutics Corporation (UTHR) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 6:30 AM EDT - 9 months ago

United Therapeutics Corporation Reports Third Quarter 2024 Financial Results

Oct 23, 2024, 7:00 AM EDT - 9 months ago

United Therapeutics Corporation Announces the 500th Lung Transplant Utilizing its Centralized Ex Vivo Lung Perfusion Service

Oct 23, 2024, 6:30 AM EDT - 9 months ago

United Therapeutics Corporation to Report Third Quarter 2024 Financial Results Before the Market Opens on Wednesday, October 30, 2024

Sep 24, 2024, 7:00 AM EDT - 10 months ago

United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the CHEST 2024 Annual Meeting

Sep 10, 2024, 7:00 AM EDT - 11 months ago

United Therapeutics Publishes its 2024 Corporate Responsibility and Public Benefit Report Highlighting its Progress Toward a Future Where No Patient Gets Left Behind—Ever

Aug 30, 2024, 12:02 PM EDT - 11 months ago

United Therapeutics Shares Thrive

Aug 28, 2024, 7:00 AM EDT - 11 months ago

United Therapeutics Corporation to Present at Upcoming Investor Conferences

Aug 19, 2024, 10:00 PM EDT - 11 months ago

United Therapeutics: Economics Support Compounding Ability

Jul 31, 2024, 11:28 AM EDT - 1 year ago

United Therapeutics Corporation (UTHR) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 6:30 AM EDT - 1 year ago

United Therapeutics Corporation Reports Second Quarter 2024 Financial Results

Jul 24, 2024, 7:00 AM EDT - 1 year ago

United Therapeutics Corporation to Report Second Quarter 2024 Financial Results Before the Market Opens on Wednesday, July 31, 2024

Jul 10, 2024, 7:00 AM EDT - 1 year ago

United Therapeutics Corporation Announces Full Enrollment of the TETON 2 Study of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis

Jun 28, 2024, 10:36 AM EDT - 1 year ago

Big Money Elevating United Therapeutics

Jun 27, 2024, 7:00 AM EDT - 1 year ago

United Therapeutics Corporation Announces Election of Jan Malcolm to its Board of Directors

Jun 5, 2024, 7:00 AM EDT - 1 year ago

United Therapeutics Corporation to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

May 1, 2024, 2:46 PM EDT - 1 year ago

United Therapeutics Corporation (UTHR) Q1 2024 Earnings Call Transcript

May 1, 2024, 6:30 AM EDT - 1 year ago

United Therapeutics Corporation Reports First Quarter 2024 Financial Results

Apr 26, 2024, 2:02 PM EDT - 1 year ago

CORRECTING and REPLACING PHOTO United Therapeutics Announces World's First Successful Xenothymokidney Transplant

Apr 24, 2024, 9:00 AM EDT - 1 year ago

United Therapeutics Announces World's First Successful Xenothymokidney Transplant

Apr 24, 2024, 7:00 AM EDT - 1 year ago

United Therapeutics Corporation to Report First Quarter 2024 Financial Results Before the Market Opens on Wednesday, May 1, 2024

Apr 16, 2024, 7:00 AM EDT - 1 year ago

United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2024 International Conference

Mar 26, 2024, 7:00 AM EDT - 1 year ago

United Therapeutics Announces the First Comprehensive Review Publication on Xenotransplantation

Mar 25, 2024, 7:00 AM EDT - 1 year ago

United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program

Mar 5, 2024, 6:00 AM EST - 1 year ago

United Therapeutics Corporation to Present at the Leerink Partners Global Biopharma Conference 2024

Feb 27, 2024, 6:00 AM EST - 1 year ago

United Therapeutics Corporation to Present at the TD Cowen 44th Annual Health Care Conference

clan Jul. 15 at 9:38 AM

1 · Reply

clan Jul. 14 at 7:45 PM

$MNKD @ItzaFugazi Question: If Teton 2 for IPF could jump $UTHR from current $297 to well over $500/sh, what would that mean for MNKD? Answer: A lot!

2 · Reply

JarvisFlow Jul. 10 at 4:09 PM

Morgan Stanley has adjusted their stance on United Therapeutics ( $UTHR ), setting the rating to Equal-Weight with a target price of 348 → 328.

0 · Reply

clan Jul. 10 at 2:37 PM

2 · Reply

grampslol Jul. 9 at 2:47 PM

0 · Reply

JarvisFlow Jul. 8 at 3:41 PM

JP Morgan updates rating for United Therapeutics ( $UTHR ) to Overweight, target set at 350 → 330.

0 · Reply

grampslol Jul. 8 at 3:10 PM

0 · Reply

Harryx1 Jul. 8 at 2:56 PM

$MNKD $UTHR

2 · Reply

Harryx1 Jul. 8 at 2:42 PM

$MNKD $UTHR https://www.researchgate.net/publication/393364987_Practical_Considerations_for_Managing_Patients_on_Tyvaso_DPI_Treprostinil_Inhalation_Powder

1 · Reply

HanksterGangster Jul. 7 at 2:59 PM

$UTHR - indicators suggest good entry point towards filling the huge gap to $235. Slow recovery in the making.

0 · Reply

clan Jul. 6 at 11:17 AM

$LQDA $UTHR @RJRNAB @BullRun4 @EatingCatPoop Liquidatia's CEO recently expressing the concerns for: 1. future potential dilution needs, 2. the manufacturing facility's capacity constraints, and 3. Yutripia's lengthy list of likely adverse events 💩👖 & 🤮, is likely what has LQDA stock price falling like a knife 🔪.📉

1 · Reply

stevemano Jul. 3 at 1:07 PM

$MNKD $UTHR I am now owning more than I ever have! I traded a 1/3 in the 7’s. Got a lot more in 3’s and will continuously be buying more $MNKD shares. Gltu! GLTUA!

0 · Reply

sanchovia Jul. 3 at 11:47 AM

$MNKD Here is how it will probably play, as it has in the past on positive news. $UTHR reports huge TrepT numbers, none $MNKD shareholders connect the dots, SP appreciates. I am not too early I believe. The core is intact. I want more trading shares for the jolt upwards back to, hopefully $5+. Down here at $3.50 it’s a crime that management does do anything.

1 · Reply

stevemano Jul. 1 at 2:41 PM

$MNKD what is quite interesting is the 5 year chart pattern for $UTHR is very similar to the mankind corporations stock pattern. Very

0 · Reply

JarvisFlow Jul. 1 at 10:00 AM

B of A Securities has adjusted their stance on United Therapeutics ( $UTHR ), setting the rating to Neutral with a target price of 314 → 321.

0 · Reply

grampslol Jun. 30 at 11:37 PM

With so much heavy competition in pah- ild, ipf how much longer will $UTHR have $MNKD cut into their treprostinal franchise? We'll see soon enough when the s&m Agreement gets the sanofi treatment. It's only about #Affizzle #dontblameceo

1 · Reply

JarvisFlow Jun. 30 at 5:00 PM

UBS updates rating for United Therapeutics ( $UTHR ) to Buy, target set at 410 → 385.

0 · Reply

high_tech_texan Jun. 30 at 2:25 PM

$UTHR In at $284.60 pre-markets (500 shares) and out at ≈$288.60 within an hour. I'm pretty sure this is going higher, but I'll take the $2,000 profit. Good luck y'all.

0 · Reply

grampslol Jun. 29 at 11:37 AM

To review : 34 yr old $MNKD only drug approved 11 yrs ago for diabetes is a utter non-competive failure. Scrips Week ending 6/20/2025 new 400 refills 517. Joke unfunded micro pipe that BP has no interest in, can't retain employees, 800million authorized shares waiting to be converted to outstanding, massive Shelf, huge ATM , insiders getting the gold retail sh gets shafted. Nothing is coming to revive #afizzle . Pumpers lie about pennyland $MNKD to trick the naive to buy. Ignore the noise $UTHR will get crushed by $LQDA and uthr will sanofiy mnkd . #reality

3 · Reply

jerchess Jun. 28 at 3:04 PM

$AMPH $MNKD $UTHR makes sense. Potential 10 bagger in a couple years. For now, I’m in other things, but I’ll be back.

1 · Reply

clan Jun. 28 at 3:00 PM

$MNKD $UTHR $AMPH If Afrezza pediatrics, Clofazimine (CIS), and Nintedanib DPI all get FDA approved, whether Mannkind sells alone or with p'ships, MNKD becomes a $50+ stock. APPROVALS {and eventual accretive} ADDS TO MNKD SHARE PRICE [Before EOY 2028]: +$10 -- pediatric Afrezza + $3 -- gestational Afrezza + $7 -- Clofazimine nebulized (CIS) + $3 -- Clofazimine DPI +$12 -- Nintedanib DPI + $4 -- TYVASO for IPF + $6 -- TYVASO for PPF @jerchess

1 · Reply

wwmeinc Jun. 27 at 5:47 PM

$GOSS ...I am guessing the 2 new entrants are pulling in some funds...patients...well....it is a huge mkt...so only time will tell on that front but we have a very good product(that actually works to keep patients/users from needing more therapies)...so just a matter of hanging with these wild swings by all accounts...competition does or should make all mgmt teams that much more efficient or so the thinking goes :) Good trading...glta $INSM $LQDA $UTHR $MRK

0 · Reply

Market Cap	13.33B
Revenue (ttm)	2.88B
Net Income (ttm)	1.20B
EPS (ttm)	N/A
PE Ratio	11.98
Forward PE	11.03
Profit Margin	41.53%
Debt to Equity Ratio	0.03

Volume	303,168
Avg Vol	569,122
Day's Range	N/A - N/A
Shares Out	45.11M
Stochastic %K	73%
Beta	0.53
Analysts	Strong Sell
Price Target	$383.92